Creatine and Depression in Women: What a Landmark Clinical Trial Found

Creatine and Depression in Women: What a Landmark Clinical Trial Found

Important note: This article discusses research on creatine as a supplement studied in clinical settings alongside standard depression treatment. It is not medical advice. If you are experiencing depression, please speak with a healthcare professional. Do not stop or modify any prescribed medication without consulting your doctor.

---

Depression affects women at roughly twice the rate of men. Standard treatments — antidepressants, therapy — work for many people, but a significant portion of patients don't respond adequately or respond too slowly. Researchers have been exploring whether creatine, a cellular energy molecule with an established safety record, might improve outcomes when added to existing treatment.

The findings are more compelling than most people realize.

The Lyoo 2012 Trial: The Study That Started Everything

In 2012, Dr. In Kyoon Lyoo and colleagues at Seoul National University published a landmark study in the American Journal of Psychiatry — one of the highest-impact journals in psychiatry. It remains the largest randomized controlled trial of creatine augmentation for depression to date.

The setup: 52 women with major depressive disorder (MDD) were enrolled in an 8-week double-blind, placebo-controlled trial. All participants received the antidepressant escitalopram (a common SSRI). Half also received 5g/day of creatine monohydrate; half received a placebo. Depression severity was measured using the Hamilton Depression Rating Scale (HAM-D).

The results were striking. Compared to the placebo group, the creatine group showed significantly greater improvements in depression scores — and crucially, these improvements appeared as early as week 2. Standard SSRIs typically take 4–6 weeks to show meaningful effects. The creatine group maintained superior improvement at weeks 4 and 8.

Adverse events were minimal and comparable between groups. The authors concluded that creatine augmentation of SSRI treatment showed "superior efficacy, relatively good tolerability, minimal side effects, and easy attainability."

Why Women Specifically?

The Lyoo trial enrolled only women — a deliberate choice based on biological reasoning. Women have 20–30% lower creatine stores in the brain than men, and research in animal models had already suggested creatine's antidepressant effects were sex-dependent, with stronger effects in females.

A subsequent study by Kanekar et al. confirmed this in animal models: creatine not only reduced depressive symptoms in females but also enhanced the efficacy of SSRIs — a finding directly relevant to the Lyoo results.

The practical implication: if you're a woman and creatine has any mood-relevant effect, the biology suggests it's more likely to be relevant for you than for men.

The Mechanism: Brain Energy and Mood

Why would an energy supplement affect depression? The answer lies in what depression actually does to the brain at the cellular level.

Depression is associated with reduced cerebral energy metabolism — brain cells are less efficient at producing ATP. This energy deficit affects the prefrontal cortex and limbic system, the regions responsible for mood regulation, motivation, and emotional processing. Standard antidepressants target neurotransmitter levels (serotonin, norepinephrine), but they don't directly address the underlying energy deficit.

Creatine works through a parallel and complementary pathway: by increasing phosphocreatine availability in brain cells, it helps neurons regenerate ATP more efficiently. This is why adding creatine to an SSRI — which addresses neurotransmitter imbalance — may produce faster and stronger effects than either alone. The two approaches attack different aspects of the same problem.

A study by Kondo et al. (2016) used phosphorus-31 MRI to directly measure brain phosphocreatine levels in adolescent girls with SSRI-resistant depression. They found that elevated brain phosphocreatine levels — which creatine supplementation produces — were directly linked to improved mood scores. The brain energy connection is real and measurable.

Dietary Creatine and Depression Risk in the General Population

Beyond clinical trials, population-level data also points in the same direction. A study using data from the National Health and Nutrition Examination Survey (NHANES) — a large, nationally representative U.S. dataset — found an inverse association between dietary creatine intake and depression risk. Higher creatine consumption from food was associated with lower odds of depression (adjusted odds ratio = 0.68).

This is an observational finding, not proof of causation. But it's consistent with the trial data and supports the biological hypothesis.

What About SSRIs That Aren't Working?

A 2017 study by Kious et al. looked specifically at adults with MDD who were either unmedicated or not responding to SSRIs. Creatine supplementation significantly alleviated depression symptoms compared to placebo in this treatment-resistant group.

A separate open-label pilot study by Kious and colleagues examined women with MDD who had failed to respond to SSRIs or SNRIs. Adding 5g/day of creatine monohydrate (plus 5-HTP) over 8 weeks produced meaningful reductions in depression scores. This suggests creatine may be particularly relevant for women who haven't responded adequately to standard antidepressant treatment — though larger randomized trials are needed to confirm this.

What This Research Does NOT Show

To be clear about what the evidence supports and doesn't support:

• Creatine has NOT been studied as a standalone treatment for clinical depression. Every positive trial used it as an adjunct — added on top of existing antidepressant treatment, not replacing it
• The evidence base is still relatively small. The Lyoo 2012 trial — the largest RCT — had only 52 participants. Larger replication studies are needed
• Creatine should not be used to replace prescribed antidepressants. Anyone experiencing depression should be under the care of a mental health professional
• One trial in bipolar depression raised a caution: two participants showed switches to hypomania/mania. People with bipolar disorder should discuss creatine with their psychiatrist before considering it

The Mood Connection Beyond Clinical Depression

For women who don't have clinical MDD but experience mood disruption — particularly related to hormonal cycles, perimenopause, postpartum period, or chronic stress — the emerging evidence is also relevant.

The Smith-Ryan et al. 2025 review in the Journal of the International Society of Sports Nutrition noted that creatine may improve mood and cognitive function and potentially alleviate symptoms of depression, with effects particularly relevant across female hormonal life stages. The CONCRET-MENOPA 2026 trial found that menopausal women taking creatine reported fewer mood swings compared to placebo.

These aren't clinical depression endpoints — they're quality-of-life findings. But they suggest creatine's mood-relevant effects extend beyond the clinical population.

The Practical Picture

For women who are currently under medical care for depression and interested in discussing creatine with their doctor, the relevant facts to bring to that conversation:

• The Lyoo 2012 trial (Am J Psychiatry) showed creatine augmentation of SSRIs produced faster, stronger improvement in HAM-D scores in women with MDD
• The dose used was 5g/day of creatine monohydrate — the same standard supplement dose recommended for athletic performance
• Safety profile was excellent and comparable to placebo
• The mechanism (brain energy restoration) is complementary to, not competitive with, standard antidepressant mechanisms

For women without clinical depression who are interested in creatine's general mood and energy effects, the same 3–5g/day of creatine monohydrate that supports physical performance and cognitive function is the appropriate starting point.

Creatine won't replace therapy or medication for clinical depression. But the evidence that it can meaningfully augment treatment outcomes — particularly in women — is now published in top-tier psychiatric journals. That's worth knowing.